Literature DB >> 21169243

CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma.

Guoan Chen1, So Hee Kim, Amanda N King, Lili Zhao, Robert U Simpson, Paul J Christensen, Zhuwen Wang, Dafydd G Thomas, Thomas J Giordano, Lin Lin, Dean E Brenner, David G Beer, Nithya Ramnath.   

Abstract

PURPOSE: The active form of vitamin D, 1α,25-dihydroxyvitamin D(3) (1,25-D(3)), exerts antiproliferative effects in cancers, including lung adenocarcinoma (AC). CYP24A1 is overexpressed in many cancers and encodes the enzyme that catabolizes 1,25-D(3). The purpose of our study was to assess CYP24A1 as a prognostic marker and to study its relevance to antiproliferative activity of 1,25-D(3) in lung AC cells. EXPERIMENTAL
DESIGN: Tumors and corresponding normal specimens from 86 patients with lung AC (stages I-III) were available. Affymetrix array data and subsequent confirmation by quantitative real time-PCR were used to determine CYP24A1 mRNA expression. A subsequent validation set of 101 lung AC was used to confirm CYP24A1 mRNA expression and its associations with clinical variables. The antiproliferative effects of 1,25-D(3) were examined using lung cancer cell lines with high as well as low expression of CYP24A1 mRNA.
RESULTS: CYP24A1 mRNA was elevated 8- to 50-fold in lung AC (compared to normal nonneoplastic lung) and significantly higher in poorly differentiated cancers. At 5 years of follow-up, the probability of survival was 42% (high CYP24A1, n = 29) versus 81% (low CYP24A1, n = 57) (P = 0.007). The validation set of 101 tumors showed that CYP24A1 was independently prognostic of survival (multivariate Cox model adjusted for age, gender, and stage, P = 0.001). A549 cells (high CYP24A1) were more resistant to antiproliferative effects of 1,25-D(3) compared with SKLU-1 cells (low CYP24A1).
CONCLUSIONS: CYP24A1 overexpression is associated with poorer survival in lung AC. This may relate to abrogation of antiproliferative effects of 1,25-D(3) in high CYP24A1 expressing lung AC. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21169243      PMCID: PMC3058389          DOI: 10.1158/1078-0432.CCR-10-1789

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  ONCOMINE: a cancer microarray database and integrated data-mining platform.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

2.  Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling.

Authors:  R J Bernardi; D L Trump; W D Yu; T F McGuire; P A Hershberger; C S Johnson
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

Review 3.  Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma.

Authors:  M C McElwain; R A Modzelewski; W D Yu; D M Russell; C S Johnson
Journal:  Am J Otolaryngol       Date:  1997 Sep-Oct       Impact factor: 1.808

4.  Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones.

Authors:  Ahmed S Aboraia; Bart Makowski; Alba Bahja; David Prosser; Andrea Brancale; Glenville Jones; Claire Simons
Journal:  Eur J Med Chem       Date:  2010-07-08       Impact factor: 6.514

5.  Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)

Authors:  M M Braun; K J Helzlsouer; B W Hollis; G W Comstock
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

Review 6.  Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study.

Authors:  R M Bostick; J D Potter; T A Sellers; D R McKenzie; L H Kushi; A R Folsom
Journal:  Am J Epidemiol       Date:  1993-06-15       Impact factor: 4.897

7.  Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer.

Authors:  K Mimori; Y Tanaka; K Yoshinaga; T Masuda; K Yamashita; M Okamoto; H Inoue; M Mori
Journal:  Ann Oncol       Date:  2004-02       Impact factor: 32.976

8.  Gene-expression profiles predict survival of patients with lung adenocarcinoma.

Authors:  David G Beer; Sharon L R Kardia; Chiang-Ching Huang; Thomas J Giordano; Albert M Levin; David E Misek; Lin Lin; Guoan Chen; Tarek G Gharib; Dafydd G Thomas; Michelle L Lizyness; Rork Kuick; Satoru Hayasaka; Jeremy M G Taylor; Mark D Iannettoni; Mark B Orringer; Samir Hanash
Journal:  Nat Med       Date:  2002-07-15       Impact factor: 53.440

9.  Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.

Authors:  M Liu; M H Lee; M Cohen; M Bommakanti; L P Freedman
Journal:  Genes Dev       Date:  1996-01-15       Impact factor: 11.361

10.  Chromosomal changes during development and progression of prostate adenocarcinomas.

Authors:  H Zitzelsberger; D Engert; A Walch; U Kulka; M Aubele; H Höfler; M Bauchinger; M Werner
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more
  42 in total

1.  A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay.

Authors:  Jan H Beumer; Robert A Parise; Beatriz Kanterewicz; Martin Petkovich; David Z D'Argenio; Pamela A Hershberger
Journal:  Steroids       Date:  2012-01-20       Impact factor: 2.668

2.  The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independent of its catalytic activity.

Authors:  Wei Huang; Paramita Ray; Wenbin Ji; Zhuwen Wang; Derek Nancarrow; Guoan Chen; Stefanie Galbán; Theodore S Lawrence; David G Beer; Alnawaz Rehemtulla; Nithya Ramnath; Dipankar Ray
Journal:  J Biol Chem       Date:  2020-03-12       Impact factor: 5.157

3.  A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.

Authors:  N Ramnath; S Daignault-Newton; G K Dy; J R Muindi; A Adjei; V L Elingrod; G P Kalemkerian; K B Cease; P J Stella; D E Brenner; S Troeschel; C S Johnson; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-23       Impact factor: 3.333

Review 4.  Cytochrome P450-mediated metabolism of vitamin D.

Authors:  Glenville Jones; David E Prosser; Martin Kaufmann
Journal:  J Lipid Res       Date:  2013-04-06       Impact factor: 5.922

5.  CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells.

Authors:  Qiuhong Zhang; Beatriz Kanterewicz; Shama Buch; Martin Petkovich; Robert Parise; Jan Beumer; Yan Lin; Brenda Diergaarde; Pamela A Hershberger
Journal:  Mol Cell Endocrinol       Date:  2012-02-22       Impact factor: 4.102

Review 6.  24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics.

Authors:  Wei Luo; Pamela A Hershberger; Donald L Trump; Candace S Johnson
Journal:  J Steroid Biochem Mol Biol       Date:  2012-10-08       Impact factor: 4.292

7.  PKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.

Authors:  Holly P Quach; Qi J Yang; Edwin C Chow; Donald E Mager; Stacie Y Hoi; K Sandy Pang
Journal:  Br J Pharmacol       Date:  2015-05-15       Impact factor: 8.739

Review 8.  The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms.

Authors:  Meis Moukayed; William B Grant
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

9.  Cellular apoptosis susceptibility protein (CAS) suppresses the proliferation of breast cancer cells by upregulated cyp24a1.

Authors:  Mei Ye; Ruigang Han; Jianwu Shi; Xunda Wang; Allan Z Zhao; Fanghong Li; Hao Chen
Journal:  Med Oncol       Date:  2020-04-08       Impact factor: 3.064

Review 10.  Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations.

Authors:  Qiuhong Zhang; Beatriz Kanterewicz; Suzanne Shoemaker; Qiang Hu; Song Liu; Kristopher Atwood; Pamela Hershberger
Journal:  J Steroid Biochem Mol Biol       Date:  2012-09-28       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.